Extremely few cases of overdosage have been reported; contact the company for further information.
In cases of severe renal insufficiency.
Harmful to people on a low potassium diet.
Hypersensitivity to the active substance(s) or to any of the excipients.
None
| System Organ Class | Common >1/100, <1/10 | Uncommon >1/1000, <1/100 | Very rare <1/10,000, Not known (cannot be estimated from the available data) |
| Immune system disorders | anaphylactic reaction | ||
| Gastrointestinal disorders | blackening of the stool | nausea, vomiting, constipation, diarrhoea | |
| Skin and subcutaneous tissue disorders | rash, pruritus |
No relevant pre-clinical safety data has been generated.
For the treatment of gastric and duodenal ulcers.
The active constituent exerts a local healing effect at the ulcer site, and by eradication or reduction of Helicobacter pylori defers relapse.
The action is local in the gastro-intestinal tract.
Prolonged use of high doses of bismuth compounds is not recommended because this has occasionally led to reversible encephalopathy. It is, not advisable to take other bismuth-containing drugs concomitantly.
Contains approximately 2 mmol (approximately 40 mg) potassium per tablet. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.
None reported.
For Adults, and the Elderly:
One tablet to be taken four times a day, half an hour before each of the three main meals and two hours after the last meal of the day, or
Two tablets to be taken twice daily, half an hour before breakfast and half an hour before the evening meal, or
As directed by the physician
The maximum duration for one course of treatment is two months; Helinoltab should not be used for maintenance therapy.
For children:
Not recommended.
None
